Pharmaceuticals India

India Prostate Cancer Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

India Prostate Cancer Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Stage, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $287.9 Mn Placeholder estimate
Estimate 2025 $320.5 Mn 2% of the global market
Projected 2034 $839.9 Mn 162.1% Adds $519.5 Mn over 9 forecast years
CAGR 2025–2034 11.3% Faster than 53% of 180 Pharmaceuticals markets here
Key players 5
  • India is 1.96% of the global market.
  • In APAC, the largest is China at $1.20 Bn.
  • Fastest growing: India (this report) at 11.3% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$519.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Prostate Cancer Therapeutics Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $287.9 Mn — —
2025 (base) $320.5 Mn +$32.5 Mn —
2026 (forecast) $356.7 Mn +$36.2 Mn +11.3%
2027 (forecast) $397.0 Mn +$40.3 Mn +23.9%
2028 (forecast) $441.8 Mn +$44.9 Mn +37.9%
2029 (forecast) $491.8 Mn +$49.9 Mn +53.5%
2030 (forecast) $547.3 Mn +$55.6 Mn +70.8%
2031 (forecast) $609.2 Mn +$61.9 Mn +90.1%
2032 (forecast) $678.0 Mn +$68.8 Mn +111.6%
2033 (forecast) $754.7 Mn +$76.6 Mn +135.5%
2034 (forecast) $839.9 Mn +$85.3 Mn +162.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Prostate Cancer Therapeutics Market Analysis at a glance
Market size, 2025$320.5 Mn placeholder estimate
Forecast, 2034$839.9 Mn placeholder estimate
Growth (CAGR), 2025–203411.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, stage and end user (see all)
Key playersJohnson & Johnson, Pfizer Inc., Astellas Pharma Inc., Bayer AG, Novartis AG (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
Active clinical trials18 in IndiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Prostate Cancer Therapeutics Market Analysis Executive Summary

Prostate cancer therapeutics include hormone therapies, androgen receptor inhibitors, PARP inhibitors and radioligand therapy.

Key segments of the prostate Cancer Therapeutics market include drug class (Androgen Receptor Inhibitors, GnRH Therapy and Radioligand Therapy) and stage (Localized, Metastatic Hormone-Sensitive and Castration-Resistant).

Bar chart: India Prostate Cancer Therapeutics market size, 2024–2034, placeholder estimates. $287.9 Mn in 2024, $320.5 Mn in 2025 and $839.9 Mn in 2034, 11.3% CAGR.
India Prostate Cancer Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Prostate Cancer Therapeutics Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the prostate Cancer Therapeutics market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the prostate Cancer Therapeutics market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the prostate Cancer Therapeutics market, especially in low- and middle-income countries.

Competitive Landscape for Prostate Cancer Therapeutics Market in India

The prostate Cancer Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Prostate Cancer Therapeutics Market in India

Prostate Cancer Therapeutics in India: rules, payment and research

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2] ClinicalTrials.gov lists 18 studies on Prostate Cancer Therapeutics that are recruiting, active or about to start in India.⁠[3]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for prostate Cancer Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Prostate Cancer Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Prostate Cancer Therapeutics in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 11th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Prostate Cancer Therapeutics market in India?
Placeholder estimate: about $320.5 Mn in 2025, rising to about $839.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Prostate Cancer Therapeutics market in India growing?
Placeholder estimate: about 11.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Prostate Cancer Therapeutics market report cover?
The report splits the market by drug class (Androgen Receptor Inhibitors, GnRH Therapy, Radioligand Therapy, PARP Inhibitors and more), stage (Localized, Metastatic Hormone-Sensitive, Castration-Resistant) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Prostate Cancer Therapeutics market?
Key players include Johnson & Johnson, Pfizer Inc., Astellas Pharma Inc., Bayer AG and Novartis AG.
What is driving the Prostate Cancer Therapeutics market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the prostate Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
Who regulates Prostate Cancer Therapeutics in India?
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How many clinical trials on Prostate Cancer Therapeutics are running in India?
18 studies are recruiting, active or about to start in India, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in India. Retrieved 12 Nov 2026.
How much research is published on Prostate Cancer Therapeutics?
PubMed lists 28 papers on Prostate Cancer Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in India

See all

Related on oncology and men's health

See the topic